2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative An.

Slides:



Advertisements
Similar presentations
ACR – EULAR Classification Criteria for Systemic Sclerosis May 25, 2013 Sindhu Johnson MD PhD.
Advertisements

OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
Early detection of pulmonary involvement in scleroderma patients By Mohamed Mostafa Metwally, MD, FCCP Assistant professor of chest diseases Assiut University.
Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative van.
PROTOCOL 588: OVERALL ASSESSMENT Concept is sound, well supported Vector is safe Transgene product is reasonably safe Overall, a phase I study seems acceptable.
Author: Cumurciuc Mihai Co-author:Silvia Ioana Morar Coordinator: Dr. Parvu Mirela.
Undifferentiated Connective Tissue Disease (What is the relationship between UCTD and SLE?) R. John Looney, MD Stephen and Elise Rosenfeld Distinguished.
Prevalence and clinical risk factors for interstitial lung disease in rheumatoid arthritis in a resource limited setting A Dasgupta, P Bhattacharyya, S.
Serum Dickkopf-1 ( DKK-1) and Arthritis in Systemic Lupus Erythematosus Patients S. I. Nasef, H. H. Omar Samah Ismail Nasef MD, MRCP Rheumatology UK Lecturer.
Dr. Ashwin Kulkarni M.S.Ramaiah Medicial College Bangalore India
4. Rheumatologic conditions
Fig 1: Skin thickening and sclerodactyly Fig 2: Digital tip ulcers
EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD)
2015 Gout Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative Tuhina Neogi,1 Tim.
Professor, Rheumatology Division, Ankara University Medical Faculty
EULAR Study Group on Systemic Lupus Erythematosus (SLE) Dimitrios T
Approach to diagnosis of Rheumatoid arthritis
pSS: primary SS; Scl: scleroderma.
My Treatment Approach to Rheumatoid Arthritis
Albarouni, Mohammed 1, Becker, Ingrid 2, Horneff, Gerd 1
Copyright © 2004 American Medical Association. All rights reserved.
الوحدة 20 مهارات التواصل مع الآخرين
EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD) V. Smith*1, A. Herrick2, A. Sulli3 and M. Cutolo3 1Ghent University Hospital, University.
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Figure 1 Historical evolution of the clinical classification and
Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.
EULAR Study Group on Systemic Lupus Erythematosus (SLE) Dimitrios T
My Treatment Approach to Rheumatoid Arthritis
EULAR Study Group for Collaborative Research
Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.
European League Against Rheumatism/American College of Rheumatology classification criteria probability of having idiopathic inflammatory myopathies (IIMs)
Improving the Recognition and Diagnosis of Fibromyalgia
Figure 3 Simplified EULAR and GRAPPA
Diffuse Idiopathic Skeletal Hyperostosis (DISH) Study Group
Volume 93, Issue 1, Pages (January 2018)
Figure 3 Transcriptome studies performed in the target
Case Collection in RA: Highlights of an Interactive Workshop
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
EULAR Study Group on Registers and Observational Drug Studies (RODS)
Figure 1 Simplified EULAR and GRAPPA
Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.
Percentage of patients achieving EULAR response
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
Classification tree for subgroups of idiopathic inflammatory myopathies (IIMs). Classification tree for subgroups of idiopathic inflammatory myopathies.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
EULAR-defined characteristics describing arthralgia at risk for RA
Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.
Clinical response in patients with early and established RA at month 24. *p
Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.
Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.
Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.
Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.
Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.
ACR20/50/70 response rates at week 24 (TP1 per-protocol set).
Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.
Synovial Biopsy in Patients with UPIA
Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.
ACR responses: (A) responses at Week 52 and Week 104
Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI
Acute Phase Reactants in Patients with UPIA
EULAR Study Group on SLE
EULAR Study Group for Collaborative Research
(A) JIA-ACR30/50/70/90 response rates by visit in part 1.
 Frequency distribution of the number of fulfilled classification criteria for RA (ACR 1987) in relation to the proportion of positive anti-CCP antibodies.
ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.
Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
Presentation transcript:

2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative An Official Journal of the American College of Rheumatology ARTHRITIS & RHEUMATISM 2013 arthritis and rhematism에 싣린 Systemic sclerosis 2013년 classification criteria 에 대한 Article입니다. 저는 2년차 정다운 이고 modulator는 홍승재 교수님이 십니다. R2 정다운/ Prof. 홍승재

Introduction Systemic sclerosis : small vessel vasculopathy, production of autoantibodies, fibroblast dysfunction leading to increased deposition of extracellular matrix Standard classification criteria : 1980 ACR SSc criteria (American College of Rheumatology Systemic sclerosis criteria) Because of the insufficient sensitivity of the 1980 criteria and advances in knowledge about Systemic sclerosis ACR and the European League Against Rheumatism (EULAR) established a committee to provide a Joint proposal for new classification criteria for Systemic sclerosis criteria

The aims were to develop criteria 1) encompass a broader spectrum of Systemic sclerosis including patients in the early stage as well as those in the late stage 2) include vascular, immunologic, and fibrotic manifestations 3) feasible to use in daily clinical practice 4) in accordance with criteria used for diagnosis of Systemic sclerosis in clinical practice in accordance with : 부합하게

Table 1은 systemic sclerosis의 새로운 classification criteria를 보여줍니다. Systemic slcerosis 의 classification 을 충족시키기 위해서 9점 이상이 되야 합니다. 먼저 proximal에서 metacarphoparhalgeal joint까지 skin thickness 가 있는 경우 9점이며 Systemic sclerosis의 classification으로 충분합니다. 그러나 배제되는 criteria도 2가지가 있습니다. 첫째 scleroderma-like disorder에 해당 되는 경우, 둘째 손가락을 제외한 skin thickening은 Systemic slcerosis의 Classification 에서 제외됩니다. 나머지 7개 item 중에서 finger의 skin thicekning에 2가지 항목이 포함되며 puffy finger 2점, sclerodactly 4점이며 두가지 모두 해당될 경우에 높은 점수가 합산됩니다. 그밖에 telangiectasia 2점, 비정상적 nailflod capillaries 2점, pulmonary artery hypertension , Interstital lung disease는 한 항목으로 묶여지며 각각 2점에 해당되며 raynaud[‘s phenomenon 3점, systemic sclerosis –related autoantibodises는 3점으로 가산됩니다. 이에 첫번째 항목이 포함되지 않더라도 합산된 점수가 9점이상이면 Systemic sclerosis classification에 포함시킬 수 있겠습니다.

Table 2는 각 항목에 대한 definition을 보여 줍니다.

Table 3은 268명의systemic sclerosis, 137명의 control 을 포함하는 validation Sample의 characteristics을 보여줍니다.

Table 4를 보시면 2013년 systemic sclerosis classification 은 derivation sample 에서 sensitivity가 1980년, 2001년 이전 classification이 0.80 %, 0.76% 였던 것에 비해 0.95%로 높게 나타났으며 specificity 역시 이전 classificatin이 077%, 0,69% 인것에 비해 0.93%로 높게 나타납니다. Validation sample에서도 마찮가지로 sensitivity 0.91% specificity 0.92%로 높게 나타났습니다. 또한 질병에 이환 된지 3년 이내 비교적 질병 초기의 경우에도 validation sample 분석에 따르면 2013년 classification의 sensivitty와 specifity가높게 나타납니다.

Table 5를 보시면 38개의 case를 대상으로 새로운 classification 을 적용하여 9점 이상의 score를 얻고 systemic sclerosis로 분류된 경우와 같은 case를 1980년 criteria를 기준으로 분류한 경우 차이가 나는 것을 확인 할 수있습니다. 이전 criteria에서 systemic sclerosis로 분류된 경우는 모두 새로운 기준에서도 Systemic sclerosis로 분류 되었으나 새로운 기준에는 합당하나 이전 기준으로 는 부합하지 않는 case가 있었습니다.

Conclusion The ACR/EULAR classification criteria for SSc Include 4 items comprising the 1980 ACR classification criteria and items in criteria proposed 2001 better than 1980 ACR preliminary criteria in terms of both sensitivity and specificity more inclusive, well in patients with early disease (< 3years)